Login Register Cart 0
Generic placeholder image

Anti-Infective Agents

Editor-in-Chief

ISSN (Print): 2211-3525
ISSN (Online): 2211-3533

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Current Therapeutic Strategies for Chagas Disease

Author(s): Sangeeta Narwal, Tilak Dhanda*, Prerna Sharma, Vikas Sharma, Sanchit Dhankhar, Nitika Garg, Niladry Sekhar Ghosh and Nidhi Rani*

Volume 22, Issue 2, 2024

Published on: 20 October, 2023

Article ID: e230823220256 Pages: 11

DOI: 10.2174/2211352521666230823122601

Price: $65

Abstract

Trypanosoma cruzi, the parasite that causes Chagas disease, can only be cured with one of two drugs, benznidazole or nifurtimox. The main disadvantages of these drugs include their ineffectiveness outside of the acute or early infection phase, their unpleasant effects, and the parasite's tolerance to their activities. On the other hand, several institutions and research groups have been working on a number of ways that can help find a solution to the problem. These strategies have evolved over the last few years. Several examples of such advancements include the utilization of combination therapy, the repurposing of current treatments, and the change of dosages for traditional drugs. Research has also been conducted on antiparasitic plants and the substances that may be obtained from them, and it makes use of existing knowledge gathered through medical procedures. Some works have studied the parasite in order to identify important genes that have the potential to be used as therapeutic targets in the development of novel targeted medications. Even though a lot of these studies have shown promising results, only a small fraction of them make it to the clinical testing phase of the study. Institutions and research organizations should be rewarded for coordinating their efforts and addressing all areas of drug development, given their resources and information. Last but not least, distributing this information will result in novel Chagas disease therapies, which would assist impacted populations.

Graphical Abstract

[1]
Alonso-Padilla, J.; Cortés-Serra, N.; Pinazo, M.J.; Bottazzi, M.E.; Abril, M.; Barreira, F.; Sosa-Estani, S.; Hotez, P.J.; Gascón, J. Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. Expert Rev. Anti Infect. Ther., 2019, 17(3), 145-157.
[http://dx.doi.org/10.1080/14787210.2019.1577731] [PMID: 30712412]
[2]
Álvarez-Hernández, D.A.; Franyuti-Kelly, G.A.; Díaz-López-Silva, R.; González-Chávez, A.M.; González-Hermosillo-Cornejo, D.; Vázquez-López, R. Chagas disease: Current perspectives on a forgotten disease. Rev. Med. Hosp. Gen. (Mex.), 2018, 81(3), 154-164.
[http://dx.doi.org/10.1016/j.hgmx.2016.09.010]
[3]
Bahia, M.T.; Nascimento, A.F.S.; Mazzeti, A.L.; Marques, L.F.; Gonçalves, K.R.; Mota, L.W.R.; Diniz, L.F.; Caldas, I.S.; Talvani, A.; Shackleford, D.M.; Koltun, M.; Saunders, J.; White, K.L.; Scandale, I.; Charman, S.A.; Chatelain, E. Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease. Antimicrob. Agents Chemother., 2014, 58(8), 4362-4370.
[http://dx.doi.org/10.1128/AAC.02754-13] [PMID: 24841257]
[4]
Beaumier, C.M.; Gillespie, P.M.; Strych, U.; Hayward, T.; Hotez, P.J.; Bottazzi, M.E. Status of vaccine research and development of vaccines for Chagas disease. Vaccine, 2016, 34(26), 2996-3000.
[http://dx.doi.org/10.1016/j.vaccine.2016.03.074] [PMID: 27026146]
[5]
Bermudez, J.; Davies, C.; Simonazzi, A.; Pablo Real, J.; Palma, S. Current drug therapy and pharmaceutical challenges for Chagas disease. Acta Trop., 2016, 156, 1-16.
[http://dx.doi.org/10.1016/j.actatropica.2015.12.017] [PMID: 26747009]
[6]
Chatelain, E. Chagas disease drug discovery: Toward a new era. SLAS Discov., 2015, 20(1), 22-35.
[http://dx.doi.org/10.1177/1087057114550585] [PMID: 25245987]
[7]
Oliveira, M.T.; Branquinho, R.T.; Alessio, G.D.; Mello, C.G.C.; Nogueira-de-Paiva, N.C.; Carneiro, C.M.; Toledo, M.J.O.; Reis, A.B.; Martins-Filho, O.A.M.; Lana, M. TcI, TcII and TcVI Trypanosoma cruzi samples from Chagas disease patients with distinct clinical forms and critical analysis of in vitro and in vivo behavior, response to treatment and infection evolution in murine model. Acta Trop., 2017, 167, 108-120.
[http://dx.doi.org/10.1016/j.actatropica.2016.11.033] [PMID: 27908747]
[8]
Oliveira de Souza, L.I.; Bezzera-Silva, P.C.; do Amaral Ferraz Navarro, D.M.; da Silva, A.G.; dos Santos Correia, M.T.; da Silva, M.V.; de Figueiredo, R.C.B.Q. The chemical composition and trypanocidal activity of volatile oils from Brazilian Caatinga plants. Biomed. Pharmacother., 2017, 96, 1055-1064.
[http://dx.doi.org/10.1016/j.biopha.2017.11.121] [PMID: 29217159]
[9]
Echeverría, L.E.; Marcus, R.; Novick, G.; Sosa-Estani, S.; Ralston, K.; Zaidel, E.J.; Forsyth, C.; Ribeiro, A.L.P.; Mendoza, I.; Falconi, M.L.; Mitelman, J.; Morillo, C.A.; Pereiro, A.C.; Pinazo, M.J.; Salvatella, R.; Martinez, F.; Perel, P.; Liprandi, Á.S.; Piñeiro, D.J.; Molina, G.R. WHF IASC roadmap on chagas disease. Glob. Heart, 2020, 15(1), 26.
[http://dx.doi.org/10.5334/gh.484] [PMID: 32489799]
[10]
Fazel Nabavi, S.; Sureda, A.; Daglia, M.; Izadi, M.; Rastrelli, L.; Mohammad Nabavi, S. Flavonoids and chagas’ disease: The story so far! Curr. Top. Med. Chem., 2016, 17(4), 460-466.
[http://dx.doi.org/10.2174/1568026616666160824110141] [PMID: 27558676]
[11]
García-Huertas, P.; Cardona-Castro, N. Advances in the treatment of Chagas disease: Promising new drugs, plants and targets. Biomed. Pharmacother., 2021, 142, 112020.
[http://dx.doi.org/10.1016/j.biopha.2021.112020] [PMID: 34392087]
[12]
Mazzeti, A.L.; Capelari-Oliveira, P.; Bahia, M.T.; Mosqueira, V.C.F. Review on experimental treatment strategies against Trypanosoma cruzi. J. Exp. Pharmacol., 2021, 13, 409-432.
[http://dx.doi.org/10.2147/JEP.S267378] [PMID: 33833592]
[13]
Mazzeti, A.L.; Diniz, L.F.; Gonçalves, K.R. WonDollinger, R.S.; Assíria, T.; Ribeiro, I.; Bahia, M.T. Synergic effect of allopurinol in combination with nitroheterocyclic compounds against Trypanosoma cruzi. Antimicrob. Agents Chemother., 2019, 63(6), e02264-e18.
[http://dx.doi.org/10.1128/AAC.02264-18] [PMID: 30962342]
[14]
Gulin, J.E.N.; Eagleson, M.A.; López-Muñoz, R.A.; Solana, M.E.; Altcheh, J.; García-Bournissen, F. In vitro and in vivo activity of voriconazole and benznidazole combination on trypanosoma cruzi infection models. Acta Trop., 2020, 211, 105606.
[http://dx.doi.org/10.1016/j.actatropica.2020.105606] [PMID: 32598923]
[15]
Khare, S.; Nagle, A.S.; Biggart, A.; Lai, Y.H.; Liang, F.; Davis, L.C.; Barnes, S.W.; Mathison, C.J.N.; Myburgh, E.; Gao, M.Y.; Gillespie, J.R.; Liu, X.; Tan, J.L.; Stinson, M.; Rivera, I.C.; Ballard, J.; Yeh, V.; Groessl, T.; Federe, G.; Koh, H.X.Y.; Venable, J.D.; Bursulaya, B.; Shapiro, M.; Mishra, P.K.; Spraggon, G.; Brock, A.; Mottram, J.C.; Buckner, F.S.; Rao, S.P.S.; Wen, B.G.; Walker, J.R.; Tuntland, T.; Molteni, V.; Glynne, R.J.; Supek, F. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature, 2016, 537(7619), 229-233.
[http://dx.doi.org/10.1038/nature19339] [PMID: 27501246]
[16]
Kratz, J.M. Drug discovery for chagas disease: A viewpoint. Acta Trop., 2019, 198, 105107.
[http://dx.doi.org/10.1016/j.actatropica.2019.105107] [PMID: 31351074]
[17]
Molina, I.; Salvador, F.; Sánchez-Montalvá, A. The use of posaconazole against Chagas disease. Curr. Opin. Infect. Dis., 2015, 28(5), 397-407.
[http://dx.doi.org/10.1097/QCO.0000000000000192] [PMID: 26203852]
[18]
Monge-Maillo, B.; López-Vélez, R. Challenges in the management of Chagas disease in Latin-American migrants in Europe. Clin. Microbiol. Infect., 2017, 23(5), 290-295.
[http://dx.doi.org/10.1016/j.cmi.2017.04.013] [PMID: 28428122]
[19]
Molina-Garza, Z.J.; Bazaldúa-Rodríguez, A.F.; Quintanilla-Licea, R.; Galaviz-Silva, L. Anti-Trypanosoma cruzi activity of 10 medicinal plants used in northeast Mexico. Acta Trop., 2014, 136, 14-18.
[http://dx.doi.org/10.1016/j.actatropica.2014.04.006] [PMID: 24742906]
[20]
Morillo, C.A.; Marin-Neto, J.A.; Avezum, A.; Sosa-Estani, S.; Rassi, A., Jr; Rosas, F.; Villena, E.; Quiroz, R.; Bonilla, R.; Britto, C.; Guhl, F.; Velazquez, E.; Bonilla, L.; Meeks, B.; Rao-Melacini, P.; Pogue, J.; Mattos, A.; Lazdins, J.; Rassi, A.; Connolly, S.J.; Yusuf, S. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N. Engl. J. Med., 2015, 373(14), 1295-1306.
[http://dx.doi.org/10.1056/NEJMoa1507574] [PMID: 26323937]
[21]
Norman, F.F.; López-Vélez, R. Chagas disease: Comments on the 2018 PAHO Guidelines for diagnosis and management. J. Travel Med., 2019, 26(7), taz060.
[http://dx.doi.org/10.1093/jtm/taz060] [PMID: 31407784]
[22]
Olivera, M.J.; Fory, J.A.; Porras, J.F.; Buitrago, G. Prevalence of Chagas disease in Colombia: A systematic review and meta-analysis. PLoS One, 2019, 14(1), e0210156.
[http://dx.doi.org/10.1371/journal.pone.0210156] [PMID: 30615644]
[23]
Pérez-Molina, J.A.; Crespillo-Andújar, C.; Bosch-Nicolau, P.; Molina, I. Trypanocidal treatment of Chagas disease. Enferm Infecc Microbiol Clin (Engl Ed), 2021, 39(9), 4586-470.
[24]
Saraiva, RMC. Atividade antibacteriana de plantas medicinais frente à bactérias multirresistentes e a sua interação com drogas antimicrobianas. 2012. Available From: https://repositorio.ufpa.br/jspui/handle/2011/5619
[25]
Sánchez-Valdéz, F.J.; Padilla, A.; Wang, W.; Orr, D.; Tarleton, R.L. Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. eLife, 2018, 7, e34039.
[http://dx.doi.org/10.7554/eLife.34039] [PMID: 29578409]
[26]
Sangenito, L.S.; da Silva Santos, V.; d’Avila-Levy, C.M.; Branquinha, M.H.; Souza dos Santos, A.L.; de Oliveira, S.S.C. Leishmaniasis and Chagas disease–neglected tropical diseases: Treatment updates. Curr. Top. Med. Chem., 2019, 19(3), 174-177.
[http://dx.doi.org/10.2174/156802661903190328155136] [PMID: 30950334]
[27]
Torrico, F.; Gascon, J.; Ortiz, L.; Alonso-Vega, C.; Pinazo, M.J.; Schijman, A.; Almeida, I.C.; Alves, F.; Strub-Wourgaft, N.; Ribeiro, I.; Santina, G.; Blum, B.; Correia, E.; Garcia-Bournisen, F.; Vaillant, M.; Morales, J.R.; Pinto Rocha, J.J.; Rojas Delgadillo, G.; Magne Anzoleaga, H.R.; Mendoza, N.; Quechover, R.C.; Caballero, M.Y.E.; Lozano Beltran, D.F.; Zalabar, A.M.; Rojas Panozo, L.; Palacios Lopez, A.; Torrico Terceros, D.; Fernandez Galvez, V.A.; Cardozo, L.; Cuellar, G.; Vasco Arenas, R.N.; Gonzales, I.; Hoyos Delfin, C.F.; Garcia, L.; Parrado, R.; de la Barra, A.; Montano, N.; Villarroel, S.; Duffy, T.; Bisio, M.; Ramirez, J.C.; Duncanson, F.; Everson, M.; Daniels, A.; Asada, M.; Cox, E.; Wesche, D.; Diderichsen, P.M.; Marques, A.F.; Izquierdo, L.; Sender, S.S.; Reverter, J.C.; Morales, M.; Jimenez, W. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: A proof-of-concept, randomised, placebo-controlled trial. Lancet Infect. Dis., 2018, 18(4), 419-430.
[http://dx.doi.org/10.1016/S1473-3099(17)30538-8] [PMID: 29352704]
[28]
Rao, S.P.S.; Barrett, M.P.; Dranoff, G.; Faraday, C.J.; Gimpelewicz, C.R.; Hailu, A.; Jones, C.L.; Kelly, J.M.; Lazdins-Helds, J.K.; Mäser, P.; Mengel, J.; Mottram, J.C.; Mowbray, C.E.; Sacks, D.L.; Scott, P.; Späth, G.F.; Tarleton, R.L.; Spector, J.M.; Diagana, T.T. Drug discovery for kinetoplastid diseases: Future directions. ACS Infect. Dis., 2019, 5(2), 152-157.
[http://dx.doi.org/10.1021/acsinfecdis.8b00298] [PMID: 30543391]
[29]
Ribeiro, V.; Dias, N.; Paiva, T.; Hagström-Bex, L.; Nitz, N.; Pratesi, R.; Hecht, M. Current trends in the pharmacological management of Chagas disease. Int. J. Parasitol. Drugs Drug Resist., 2020, 12, 7-17.
[http://dx.doi.org/10.1016/j.ijpddr.2019.11.004] [PMID: 31862616]
[30]
Sánchez-Villamil, JP; Bautista-Niño, PK; Serrano, NC; Rincon, MY; Garg, NJ Potential role of antioxidants as adjunctive therapy in Chagas disease. Oxid. Med. Cell. Longev., 2020, 2020, 9081813.
[http://dx.doi.org/10.1155/2020/9081813]
[31]
Scarim, C.B.; Jornada, D.H.; Chelucci, R.C.; de Almeida, L.; dos Santos, J.L.; Chung, M.C. Current advances in drug discovery for Chagas disease. Eur. J. Med. Chem., 2018, 155, 824-838.
[http://dx.doi.org/10.1016/j.ejmech.2018.06.040] [PMID: 30033393]
[32]
Villalta, F.; Rachakonda, G. Advances in preclinical approaches to Chagas disease drug discovery. Expert Opin. Drug Discov., 2019, 14(11), 1161-1174.
[http://dx.doi.org/10.1080/17460441.2019.1652593] [PMID: 31411084]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy